# Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer

> **NCT00436215** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 55 (actual)

## Conditions studied

- Ovarian Neoplasm
- Fallopian Tube Cancer
- Primary Peritoneal Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** BAY 43-9006

## Key facts

- **NCT ID:** NCT00436215
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12-12
- **Primary completion:** 2014-06-26
- **Final completion:** 2014-09-27
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2020-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00436215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00436215, "Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00436215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*